Skip to Content

Yondelis Approval History

Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.

Development History and FDA Approval Process for Yondelis

Oct 23, 2015Approval FDA Approves Yondelis (trabectedin) for the Treatment of Specific Soft Tissue Sarcomas
Feb  3, 2015U.S. FDA Grants Priority Review for Yondelis (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Nov 24, 2014Janssen Submits NDA for Yondelis (trabectedin) for Advanced Soft Tissue Sarcoma
Apr 29, 2011Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin
Sep 10, 2009FDA Issues Complete Response Letter For Trabectedin Combined With Doxil
Nov 20, 2008Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.